Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prilosec Mixed Verdict Would Complicate Generic Marketing Exclusivity

Executive Summary

Schwarz Pharma is exploring a scenario where it would win a favorable decision in the Prilosec patent case, while generic omeprazole marketing exclusivity holder Andrx loses on non-infringement

You may also be interested in...



Generic Prilosec Launch Awaits Negotiations Between Andrx And Schwarz

Andrx is considering licensing its 180-day exclusivity for generic omeprazole to Schwarz Pharma following an Oct. 11 federal court ruling that Andrx' product infringes AstraZeneca's Prilosec patents, but Schwarz' does not

Generic Prilosec Launch Awaits Negotiations Between Andrx And Schwarz

Andrx is considering licensing its 180-day exclusivity for generic omeprazole to Schwarz Pharma following an Oct. 11 federal court ruling that Andrx' product infringes AstraZeneca's Prilosec patents, but Schwarz' does not

Prilosec OTC Switch Set For Early 2003 Following FDA “Approvable” Letter

AstraZeneca's OTC switch for Prilosec (omeprazole) will wait until 2003 after receipt of an "approvable" letter from FDA

Related Content

UsernamePublicRestriction

Register

PS039987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel